SecBot SecBot

CAPR

CAPRICOR THERAPEUTICS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001133869 Biotech & Drug Discovery
$5.74 −0.19 (−3.20%)
Oct 26 4:00 PM ET · prev $5.93
Market cap
$356.4M
Small cap
Consensus
Buy
56% Buy or better · 16 analysts
Median target
🔒 Subscribers only
Next earnings
Nov 17
in 22 days · EPS est. −$0.41
1 year
−7.1%
from $6.18 · Oct 27
30 days
−34.1%
from $8.71
52-week range
$3.85–35.34
−84% from high · low Jul 31
Avg volume 20D
3.59M
Sep 30 spike 20.57M
Short interest
18.83M
≈32.4% of shares · −4.3%
Days to cover
4.5
at average volume
Insider net
−$8.4M
0 buyers · 3 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 1 exit
SecBot read BEARISH 4 reports · 90 days
Balance 3 bearish · 0 bullish · 1 mixed oldest → newest, height = score
Avg score ·High conf. 3/4 ·Next Earnings date, Nov 17, 2026
Strongest BEARISH Millennium Management LLC filed an amended Schedule 13G disclosing a passive stake of 2.9% (1,669,083…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $8.4M.

  • InstitutionsBULLISH

    Q2 2026: 28 added (0 new), 11 trimmed or exited.

  • AnalystsBULLISH

    9 of 16 rate it Buy or better.

  • EstimatesFALLING

    Current-quarter EPS estimate $0.346 → −$0.409 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −4.3% to 18.83M shares. 4.5 days to cover, ≈32.4% of shares.

  • TrendDOWNTREND

    29% below its 50-day average.

  • SocialQUIET

    Crowd 58° (warm) this week from 2 mentions: 1 bullish, 0 bearish. No setup call.

Who's buying

13F· Q2 2026
0
new positions
1
exit
FundMoveSharesValue
STATE STREET CORPADD3,397,150$81.8M
GOLDMAN SACHS GROUP INCADD1,578,131$38.0M
FMR LLCADD1,137,730$27.4M
CITADEL ADVISORS LLCADD814,444$19.6M
MERCER GLOBAL ADVISORS INC /ADVADD802,732$19.3M
MORGAN STANLEYADD684,515$16.5M
VANGUARD PORTFOLIO MANAGEMENT LLCADD636,087$15.3M
UBS Group AGADD619,661$14.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 56% rate it Buy or better
Strong Buy3Buy6Hold7Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Sep 14, 2026B. Riley Securities
UPGRADE
UPGRADEBuy
Sep 1, 2026Piper Sandler
UPGRADE
UPGRADEOverweight
Aug 14, 2026Cantor Fitzgerald
UPGRADE
UPGRADEOverweight
Jul 31, 2026Jones Trading
DOWNGRADE
DOWNGRADEHold
Jul 30, 2026Piper Sandler
DOWNGRADE
DOWNGRADENeutral
Jul 30, 2026Cantor Fitzgerald
DOWNGRADE
DOWNGRADENeutral

Insider ledger

Form 4
$0
bought · 0 insiders
$8.4M
sold · 3 insiders
DateInsiderTypeValue
Jun 25, 2026
Krasney Karen
EVP, GENERAL COUNSEL
EXERCISE$76.6K
Jun 25, 2026
Bergmann Anthony
CHIEF FINANCIAL OFFICER
EXERCISE$76.6K
Jun 25, 2026
Krasney Karen
EVP, GENERAL COUNSEL
SELL$732.2K
Jun 25, 2026
Bergmann Anthony
CHIEF FINANCIAL OFFICER
SELL$732.2K
Jun 24, 2026
Krasney Karen
EVP, GENERAL COUNSEL
EXERCISE$1.3K
Jun 24, 2026
Bergmann Anthony
CHIEF FINANCIAL OFFICER
EXERCISE$1.3K
Jun 24, 2026
Bergmann Anthony
CHIEF FINANCIAL OFFICER
SELL$12.0K
Jun 24, 2026
Krasney Karen
EVP, GENERAL COUNSEL
SELL$12.0K

Earnings setup

Estimates
Nov 17
reports in 22 days
−$0.41
EPS estimate, this quarter
−218%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.41-$0.74–$0.87+2.7%$10.4M
Next Q-$0.08-$0.73–$3.01+13.2%$27.9M
Current FY-$1.45-$2.75–$1.70+35.9%$55.7M
Next FY-$1.45-$2.84–$0.62+1.8%$56.5M
Reddit mentions per day, 14 days
Crowd this week 58° Warm 1 bullish · 0 bearish
Mentions, 7 days 2 1 in posts · 1 in comments
Recent posts
r/pennystocks Neutral 5d ago
10 penny biotechs I'm watching and slowly adding for October/November 2026, and the one I got wrong in September.
1 upvotes · 1 comments
Recent comments
r/Shortsqueeze Bullish 1d ago
CAPR, I think Capr has a chance at squeeze. If you think CAPR can squeeze let me know in the comments.  CAPR!
All social signals and their track records

Short side

FINRA· Sep 30, 2026
18,825,352
shares short
-4.3%
vs prior settlement
4.5
days to cover
≈32.4%
of shares outstanding
Trading halts
Jul 29, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 14, 2026 SEC
Millennium Management LLC filed an amended Schedule 13G disclosing a passive stake of 2.9% (1,669,083 shares) in…
SC 13G/A — Impact 5/10
Sep 28, 2026 Other
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Sept. 28, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareho
Aug 24, 2026 SEC
Capricor Therapeutics announced that the FDA extended the PDUFA target action date for its Deramiocel BLA from August…
8-K — Impact 7/10
Aug 21, 2026 SEC
During 2026-Q2, 18 institutional buyers accumulated $29.1M in CAPR while 6 sellers reduced holdings by $53.1M, for net…
INST-CLUSTER — Impact 5/10
Jul 30, 2026 Press
The FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 against evidence supporting Deramiocel's…
Impact 7/10
Jun 30, 2026 Inst.
STATE STREET CORP — ADD
3,397,150 shares ($81.8M)
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — ADD
1,578,131 shares ($38.0M)
Jun 25, 2026 Insider
Krasney Karen acquired via exercise 24,100 shares
EVP, GENERAL COUNSEL @ $3.18 ($76.6K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 17, 2026
Earnings date
CAPR Q3 2026 Earnings Scheduled — 2026-11-17
Nov 22, 2026
FDA decision date
PDUFA: CAPR — Deramiocel in Duchenne muscular dystrophy — 2026-11-22
FDA target action date 2026-11-22 for CAPR (CAPRICOR THERAPEUTICS, INC.). Drug: Deramiocel. Indication: Duchenne muscular dystrophy. PDUFA target…
Recent
Sep 28, 2026
Press release
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Sept. 28, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors…
Sep 28, 2026
Press release
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
NEW YORK, Sept. 28, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc…
Sep 25, 2026
Press release
CAPR 3-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline
SAN FRANCISCO, Sept. 25, 2026 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP—a national plaintiffs' rights law firm with a premier securities…
Sep 24, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc…
Sep 24, 2026
Press release
CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor…

SecBot reports

11 filings · 2 press releases · 2 bullish · 2 bearish · 1 mixed · 6 neutral
All CAPR filing & press-release reports (13)